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Abstract
Background: Mutations in the dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes of
Plasmodium falciparum are associated with resistance to anti-folate drugs, most notably sulphadoxine-
pyrimethamine (SP). Molecular studies document the prevalence of these mutations in parasite populations across
the African continent. However, there is no systematic review examining the collective epidemiological significance
of these studies. This meta-analysis attempts to: 1) summarize genotype frequency data that are critical for
molecular surveillance of anti-folate resistance and 2) identify the specific challenges facing the development of
future molecular databases.
Methods: This review consists of 220 studies published prior to 2009 that report the frequency of select dhfr and
dhps mutations in 31 African countries. Maps were created to summarize the location and prevalence of the highly
resistant dhfr triple mutant (N51I, C59R, S108N) genotype and dhps double mutant (A437G and K540E) genotype in
Africa. A hierarchical mixed effects logistic regression was used to examine the influence of various factors on
reported mutant genotype frequency. These factors include: year and location of study, age and clinical status of
sampled population, and reporting conventions for mixed genotype data.
Results: A database consisting of dhfr and dhps mutant genotype frequencies from all African studies that met
selection criteria was created for this analysis. The map illustrates particularly high prevalence of both the dhfr triple
and dhps double mutant genotypes along the Kenya-Tanzania border and Malawi. The regression model shows a
statistically significant increase in the prevalence of both the dhfr triple and dhps double mutant genotypes in
Africa.
Conclusion: Increasing prevalence of the dhfr triple mutant and dhps double mutant genotypes in Africa are
consistent with the loss of efficacy of SP for treatment of clinical malaria in most parts of this continent. Continued
assessment of the effectiveness of SP for the treatment of clinical malaria and intermittent preventive treatment in
pregnancy is needed. The creation of a centralized resistance data network, such as the one proposed by the
WorldWide Antimalarial Resistance Network (WWARN), will become a valuable resource for planning timely actions
to combat drug resistant malaria.
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Background
The malaria problem
Global malaria control initiatives have a turbulent his-
tory driven by a number of biological, social, and eco-
nomic factors. The Malaria Eradication Programme
launched by the World Health Organization (WHO) in
1955 successfully eliminated malaria in many temperate
and sub-tropical regions of the world, but little progress
was made in sub-Saharan Africa. The programme con-
fronted technical challenges including, but not limited
to: anti-malarial drug resistance, insecticide resistance,
lack of infrastructure to implement and sustain control
measures, and a lack of community engagement and
participation [1]. These obstacles collectively damaged
the long-term sustainability of the eradication pro-
gramme, which was ultimately abandoned in 1969 [2].
The renewed vision for malaria control and eventual
elimination focuses on the development of new tools
and improved integration of existing interventions [3].
Financing from the Global Fund to Fight AIDS, Tuber-
culosis, and Malaria; the World Bank Malaria Booster
Program; and the U.S. President’s Malaria Initiative
(PMI) have increased funding for malaria control. One
objective of the PMI includes a 50% reduction in malaria
mortality in 15 African countries over a five-year period
by expanding the coverage of effective interventions
including: insecticide-treated mosquito nets (ITNs),
indoor residual spraying with insecticides, intermittent
preventive treatment for pregnant women (IPTp), and
artemisinin-based combination therapy (ACT) [3,4].
ACT is a vital component of the malaria control strat-
egy and currently represents the last line of defense
against infections that have developed resistance to pre-
vious anti-malarial therapies. Chloroquine (CQ) mono-
therapy was highly effective in treating malaria for
several years, but eventual appearance of CQ resistance
to P. falciparum became a major challenge for control
programs [5-8]. The onset of pervasive CQ resistance
led to its replacement with anti-folate drugs, most nota-
bly sulphadoxine-pyrimethamine (SP), as a first-line
therapy in many parts of the world. However, resistance
to anti-folate drugs emerged rapidly. ACT has since
been introduced to either work in combination with
anti-folates or replace them as first-line therapies in
many settings, reviewed in [9,10].
Monitoring anti-malarial drug resistance
Drug resistance continues to present a major threat to
remaining effective anti-malarial therapies, such as ACT,
that currently serve as a cornerstone of the malaria con-
trol strategy. Therefore, the success of control efforts
relies heavily upon surveillance methods to adequately
monitor and promptly respond to emerging resistance.
Clinical efficacy trials that measure the therapeutic fail-
ure rate following administration of a particular drug are
the gold-standard method for gauging the effectiveness
of anti-malarial therapies. However, clinical efficacy trials
are resource-intensive, making them difficult to use
broadly for surveillance purposes, reviewed in [11].
Translating a measure of drug efficacy into a reliable
assessment of drug resistance is also obscured by a num-
ber of host, drug, and parasite factors such as: acquired
immunity [12], compliance dosing [13], nutritional status
[14], pharmacokinetics [15], parasite synchronicity and
biomass [16], and endogenous parasite resistance
mechanisms, reviewed in [17]. Therefore, studies that
focus on specific interactions among host, drug, and
parasite can make costly clinical trials more informative
by helping to better differentiate and identify the role of
drug resistance.
Pharmacological and in vitro-based assays have been
used as tools to examine the role of host-drug and para-
site-drug interactions that influence clinical efficacy of
anti-malarials. Specifically, pharmacological studies con-
ducted within the context of clinical trials can enable an
examination of pharmacokinetics and pharmacody-
namics (PK-PD) and their role in therapeutic response.
An understanding of PK-PD in different clinical settings
and populations is essential to establish therapeutic drug
dosages for target groups and distinguish between true
therapeutic failures and other factors such as poor
adherence, drug quality, absorbance, and elimination.
PK-PD data is also essential if outcomes from different
clinical efficacy trials are to be accurately compared.
In vitro parasite susceptibility assays enable a measure of
intrinsic chemosensitivity of P. falciparum parasites to a
particular drug by controlling for host factors such as
acquired immunity, nutritional status, and compliance
dosing. Most in vitro studies report the 50% inhibition
concentration (IC50) of an anti-malarial drug, which in
turn serves as an indicator of parasite tolerance to the
drug. In vitro assays offer benefits, such as the ability to
quantify the parasite inhibiting properties of partner drugs
within combination therapies and identify temporal trends
by comparing the drug sensitivity profiles of frozen refer-
ence parasite lines with samples in question. Both in vitro
and pharmacological studies play an important role in dif-
ferentiating drug resistance from other potential causes of
decreased drug efficacy. Although these methods comple-
ment clinical efficacy trials to collectively identify the pre-
sence of drug resistance and help quantify its impact on
drug efficacy, they do little to propose specific parasite
resistance mechanisms.
Molecular studies examining genetic correlates of
resistance differ in scope from in vitro and pharmacolo-
gical studies in that they provide the means to identify
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genetic markers that confer resistance. Association and
genetic complementation studies have identified
and validated genetic markers of resistance for older
anti-malarial drugs, such as CQ, SP and chlorproguanil-
dapsone [18-24]. Molecular surveillance studies that
examine the prevalence and spread of these validated
markers present a practical means of monitoring
dynamic drug resistant parasite populations in different
parts of the world and could be useful in planning drug
efficacy studies [25]. Lessons learned from the identifica-
tion and epidemiological use of molecular markers of
resistance to formerly efficacious anti-malarials will
be useful for the improvement of molecular surveillance
capabilities for anti-malarials currently in use, such
as ACT.
Clinical, pharmacological, in vitro, and molecular stu-
dies each shed light on a certain aspect of drug efficacy
and drug resistance, but each also has its own set of
benefits and limitations. Lack of standardization across
studies of each type and differences in conventions for
reporting data are two pervasive problems that seriously
limit the ability to compare studies conducted at differ-
ent times and locations. In an effort to mitigate these
and other issues, the WorldWide Anti-malarial Resis-
tance Network (WWARN) has put forth a comprehen-
sive plan to network clinical, in vitro, pharmacological,
and molecular studies in a centralized database. The
proposed structure and objectives for each of the four
components of the database have been detailed in a ser-
ies of articles [11,26-28].
The need to standardize and network molecular data
is particularly pressing. The advancement of high-
throughput molecular techniques has enabled a rapid
increase in the number of molecular studies conducted
in recent years; however, a lack of meaningful ways to
compare studies severely limits the potential utility of
this valuable information. Databases that assemble the
reported frequency of resistant parasite genotypes from
multiple molecular studies can provide more compre-
hensive and easily accessible information. Drug resis-
tance maps at the London School of Tropical Medicine
and Hygiene [29] has assembled the reported frequency
of mutations associated with SP resistance across Africa.
The site includes data from approximately 100 studies
in an open-access map-based format with electronic
links leading to the articles from which the data was
derived. More recently, Picot et al [30] used a meta-ana-
lysis to show significant association between the pre-
sence of established genetic markers of resistance and
increased therapeutic failure rates for corresponding
anti-malarial drugs across a total of 92 studies con-
ducted worldwide. Unfortunately, very few studies of the
total number available in the literature met criteria for
data linkage in this meta-analysis and had to be
excluded from the study.
A growth in the number of molecular studies report-
ing the frequency of known resistance markers presents
new opportunities to assess the broader impact that
reporting conventions and study methodology may be
having on the data being produced. Some of the vari-
ables that have been proposed as potentially influential
include age and clinical status of the sampled popula-
tion, date and location of the molecular study, reviewed
in [31], and reporting conventions for polyclonal infec-
tions [32]. No previously published meta-analysis has
ever used congregated molecular data to quantitatively
assess the impact these variables may be having on the
reported frequency of mutations that confer anti-malar-
ial drug resistance. Therefore, an empirical database that
not only summarizes molecular studies but also assesses
the impact of potentially influential variables can pro-
vide a basis for standardization and help advance objec-
tives proposed by WWARN for the molecular
component of a centralized surveillance database.
Anti-folate resistance database
Resistance to anti-malarial drugs for which validated
molecular markers are available is already widespread;
however, a database that specifically assembles studies
reporting the frequency of parasite genotypes associated
with anti-folate resistance is valuable for a number of
reasons.
First, SP use in combination with artemisinin-based
derivatives [33,34] and as a monotherapy for intermit-
tent preventive therapy (IPT) in pregnant women [35]
continues in parts of Africa and has demonstrated clini-
cal efficacy, even in areas where SP is no longer used to
treat acute malaria in the general population due to
resistance. Clinical trials in these areas also suggest SP
IPT can have a protective effect against the risk of clini-
cal malaria and malaria anemia in infants [36], but in
some cases this has been associated with higher risk of
severe malaria rebound [37]. The prevalence and role of
SP resistant parasite genotypes in these populations
must be evaluated since this information may be useful
in complementing clinical studies that inform drug pol-
icy changes. Second, there are multiple anti-folate drugs
currently being administered in Africa with the same
drug targets. Trimethoprim-sulphamethoxazole, admi-
nistered as Cotrimoxazole® (CTX), is a low cost regimen
that has been shown to decrease morbidity and mortal-
ity in HIV-infected individuals [38]. However, CTX
shares the same drug targets as SP to decrease the inci-
dence of illness caused by bacterial and protozoan infec-
tions [39]. Thus, there is a concern that widespread
administration of CTX may promote cross-resistance to
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SP. Although a recent study did not find any rapid rise
in the antifolate-resistant P. falciparum genotypes fol-
lowing CTX treatment [40], continued surveillance is
necessary to assess the long term trends. Chlorprogua-
nil-dapsone is increasingly being used in Africa for
treating malaria. It has the same drug targets as SP, but
has shown to be more active in killing parasites in vitro
[41] and has been more effective in treating malaria
than SP in vivo [42,43], even when SP resistant parasite
genotypes are prevalent in the population [44,45]. Moni-
toring anti-folate resistant parasite genotypes in popula-
tions receiving CTX prophylaxis or chlorproguanil-
dapsone is critical to better understand the role these
drugs may have in inducing or curbing cross-resistance.
Anti-folate drug action and resistance mechanisms
The anti-folate class of drugs consists of compounds that
bind enzymes necessary for parasite folate biosynthesis.
The most widely used anti-malarial drugs within this
class are sulphadoxine-pyrimethamine (SP) and, more
recently, chlorproguanil-dapsone. The pyrimethamine
portion of SP and chlorcycloguanil, the active metabolite
of chlorproguanil, bind the enzyme dihydrofolate reduc-
tase (DHFR) [46]. Sulphadoxine and dapsone bind the
enzyme dihydropteroate synthase (DHPS) [45,47,48].
Both enzymes are part of the parasite folate synthetic
pathway and the inhibition of these enzymes leads to
decreased production of tetrahydrofolate [49]. Tetrahy-
drofolate is a necessary cofactor for the production of a
number of folate precursors including dTMP and
methionine. Decreased production of these precursors
severely inhibits the Plasmodium parasite life cycle [50].
Mutations in the dhfr and dhps genes of P. falciparum
parasites have been associated with decreased parasite
sensitivity to the anti-folate drugs. A change from wild-
type Ser108 to Asn108 (S108N) in dhfr is sufficient to
cause low level pyrimethamine resistance both in vitro
and in vivo [18,21,51]. This single mutation can increase
in vitro resistance to pyrimethamine by 100-fold relative
to wild-type [21]. The progressive addition of mutations
altering Cys50 to Arg (C50R), Asn51 to Ile (N51I),
Cys59 to Arg (C59R), and Ile164 to Leu (I164L) in dhfr
can yield higher levels of SP resistance in vitro and in
vivo [51-56]. Genotypes consisting of multiple mutations
in the dhfr gene have evolved in different parts of the
world (see Table 1) and are most often associated with
higher levels of resistance than the single mutant geno-
types. The triple dhfr mutant genotype consisting of
N51I, C59R, and S108N shows in vitro resistance to pyr-
imethamine that is 225 times higher than a wildtype lab
strain [41,52] and has demonstrated strong association
with in vivo SP treatment failure [32,57,58]. The Ala16
to Val (A16V) and Ser108 to Thr (S108T) mutations in
dhfr confer resistance to cycloguanil but not pyrimetha-
mine [19,20]. The addition of the N51I, C59R, and
I164L mutations in the presence of S108N confers high
levels of resistance to both pyrimethamine and cyclogua-
nil [19,20,56].
Mutations in codons Ser436 to Ala or Phe (S436A/F),
Ala437 to Gly (A437G), Lys540 to Glu (K540E), Ala581
to Gly (A581G), and Ala613 to Ser or Thr (A613S/T) in
dhps have been shown to affect parasite susceptibility to
the sulpha drugs including sulphadoxine and dapsone
[45,59,60]. The dhps A437G mutation alone predicted
clinical failure of SP in parts of Kenya [61]. Data from
various malaria endemic areas suggest asymmetric selec-
tion of resistant genotypes starting with mutations in
dhfr and followed by those in dhps [50]. Multiple mutant
dhps genotypes have also evolved in different parts of the
world (see Table 1). The double dhps mutant genotype
consisting of A437G and K540E is highly associated with
in vivo clinical failure independently [58,62]. However,
the quintuple mutant genotype consisting of the double
dhps mutant genotype (A437G, K540E) in combination
with the dhfr triple mutant genotype (S108N, N51I,
C59R) is a better predictor of clinical failure than either
multiple mutant genotype alone [58,63].
Objectives
The objective of this meta-analysis are to 1) provide a
comprehensive database of reported frequencies for
resistant dhfr and dhps mutant genotypes in African
P. falciparum populations; 2) highlight the significance
and limitations of these studies; 3) use condensed tables,
plots, and geostatistical illustrations to present frequency
data; 4) use statistical models to describe changes in the
prevalence of select highly resistant genotypes over the
years; and 5) elucidate the impact of variables that may
influence reported genotype frequencies.
Methods
Literature search
A literature search was done using the National Library of
Medicine Pubmed/Medline search engine. Search terms
included “dihydropteroate synthase,” “dhps,” “dihydrofo-
late reductase,” “dhfr,” “Plasmodium falciparum,” “Africa,”
“sulphadoxine pyrimethamine,” “antifolate,” “drug resis-
tance,” “Fansidar.” Boolean operators were used to search
for articles using these terms in various combinations. All
variations in the spelling of these terms were accounted
for in the search. Additional articles were found through
the Related Articles search feature on the Pubmed website
and through the reference sections of candidate articles.
The Drug Resistance Maps database [29] was also used
to identify studies that may have been missed in
the Pubmed/Medline search. Each article was then
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individually screened to identify those that met the follow-
ing criteria:
1) The article must have been published in English
prior to Jan 1st, 2009 to be included.
2) The article must explicitly state or provide inter-
pretable mutation frequencies for any of the selected
codons in dhfr (16, 50, 51, 59, 108) and/or dhps
(436, 437, 540, 581, 613) to be included.
3) The article must have provided mutant frequency
data derived from pre-treatment blood isolates to be
included. Genotype frequency data derived from
patients receiving anti-malarial drugs within two
weeks of enrollment and/or patients who were deter-
mined to have therapeutic levels of anti-folate drugs
in their bloodstream at the time of enrollment were
excluded. Genotype frequency data derived from in
vitro cultured blood isolates were also excluded.
4) The study must have restricted its sampling to
blood isolates of African origin from local patient
populations to be included. Genotype frequency data
derived from travelers were excluded.
Mutant allele frequency (MAF) and mutant genotype
frequency (MGF) databases
Data reporting the frequency of mutations in dhfr and
dhps were extracted from published articles and were
summarized using two separate databases called the
Mutant Allele Frequency (MAF) database and Mutant
Genotype Frequency (MGF) database (see Additional
Files 1 &2, respectively). The MAF database reports the
frequency of mutations in dhfr and dhps for each codon
individually. Whereas, the MGF database describes the
frequency of the highly resistant dhfr triple mutant gen-
otype (N51I, C59R, S108N) and dhps double mutant
genotype (A437G, K540E) using a standardized system,
similar to the format described by Kublin et al [32].
Table 2 has been condensed to describe how genotypes
were categorized in the MGF database.
One of the major methodological differences across stu-
dies was the reporting standards for mixed mutant gen-
otypes. Mixed mutant genotypes are detected when two
or more populations of parasites with distinct genotypes
at particular codons of interest are present in a single
infection. These infections are commonly referred to as
“polyclonal” since multiple clonal populations of para-
sites are present in a single blood isolate. Varying classi-
fications for mixed genotypes can have a significant
impact on the determination of mutant genotype fre-
quency; particularly in high transmission settings where
polyclonal infections have been reported in greater than
50% of sampled isolates, reviewed in [64].
A majority of studies included in this review used the
Restriction Fragment Length Polymorphism (RFLP)
Table 1 Mutant genotypes associated with high levels of anti-folate resistance
dhfr genotypes Location Reference
N51I/C59R/S108N Asia, Africa Reviewed in [17]
N51I/C59R/S108N/I164L Asia, Africa Reviewed in [17]; [88]
N51I/S108N/I164L South America, Africa [96]; [97]; [98]; [88]
C50R/N51I/S108N South America [96]
dhps genotypes Location Reference
A437G/K540E Africa, Asia, Indonesia Reviewed in [17]; [99]; [100]
S436A/A437G Africa [101]; [79]
A437G/A581G South America [102]
A437G/K540E/A581G Asia, South America [96]; [103]; [97]
S436A/A437G/K540E/A581G; S436A/A437G/K540E Asia [104]; [105]
Table 2 dhfr and dhps genotype classification
dhfr codon dhps codon
N51I C59R S108N A437G K540E
Single X Single X
X X
X
Double X X Double X X
X X
X X
Triple X X X
Each row represents a mutant genotype for either the dhfr gene or dhps
gene. A white box represents a wildtype codon whereas a box with an “X”
represents a mutant codon. The MGF database (Additional File 2) reports the
frequency of mutant genotypes using the single, double, and triple mutant
categories for dhfr and the single and double mutant categories for dhps.
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technique to differentiate between the mutant and wild-
type form at codons of interest. Since this is an indirect
method to detect codon change it has some inherent
limitations in identifying appearance of new mutations
and in accurately genotyping mixed infections [65]. A
number of more recent studies use different methods to
detect mutant genotypes including pyrosequencing,
direct sequencing, and RT-PCR methods. However, each
of these methods can have a different sensitivity and
specificity in detecting various mutations accurately and
thus can contribute to some variation in estimating the
frequency of mutant genotypes. Since there is not a uni-
versal convention for determining and reporting differ-
ent mutants, it was a challenge to compare different
studies. Therefore, a rubric (Table 3) was created to
categorize various reporting standards and establish a
standardized approach to extract mutant genotype fre-
quency data. The categories within the rubric are: com-
bined, excluded, separate, split, and N/A. The combined
category was used to describe studies that reported
mixed mutant genotypes as pure mutants. The excluded
category was used to describe studies that completely
excluded mixed genotypes from the analysis. The sepa-
rate category was used to describe studies that reported
the mixed genotype frequency separate from the pure
mutant or pure wildtype genotype frequencies. For this
review, mixed genotype frequencies were reported sepa-
rately from the pure mutant or pure wildtype genotype
frequencies in the MGF database whenever possible.
The split category was used to describe studies that con-
sidered mixed genotypes to be both mutant and wild-
type; therefore, they were split between both. For this
review, mixed genotypes were only split in the MAF
database whenever possible. Finally, the N/A category
was used to describe studies that made no mention of
mixed genotypes when reporting genotype frequency.
The mixed mutant category, year of study, age descrip-
tion of sampled population, and frequency data corre-
sponding to each study can be found in the MAF and
MGF databases. The ID number for each study links
directly to a citation for the article from which the data
was extracted (see Additional File 3). Calculations used
to determine the mutant, wildtype, and mixed frequen-
cies for studies within each category are shown in
Table 3.
Maps and Time plots of dhfr triple mutant and dhps
double mutant genotypes
Maps describing the distribution and prevalence of the
dhfr triple mutant genotype and the dhps double mutant
genotype (see Figures 1 and 2, respectively) were created
using ArcGIS 9.3.1 software. Locality coordinates were
determined by searching for locality names in the
Europa 2009 coordinate database. This database con-
tains approximately 300,000 points with coordinate data
along with identifiable geographical features and politi-
cal boundaries. A majority, 75%, of the study sites were
found in Europa. The remaining 25% could not be
found; therefore, a search of academic journals through
the Pubmed/Medline databases was conducted to find
articles that describe these localities along with maps or
coordinate information. The academic journal search
yielded accurate locality descriptions for a majority of
the remaining 25%; however, a few studies (~5% of the
total) were only described by their proximity to political
boundaries or geographical features such as rivers,
mountains, or valleys. The extent error associated with
these localities is greater, but was considered sufficient
for the scale of the continent-wide map. These methods
yielded geographic coordinates for each study. Coordi-
nates were plotted using a black circle denoting the
location of the study. The size of the circle is propor-
tional to the number of samples examined.
An inverse distance weighted (IDW) algorithm was
used to provide a snapshot of dhfr triple and dhps dou-
ble mutant genotype prevalence in parts of Africa where
studies have not been conducted. The IDW method
assumes that the prevalence of the mutant genotype
near observed data points are the most similar with
decreasing similarity as distance from the observed data
point increases. The amount of influence a given data
point has at a certain distance is also influenced by a
power value (p) that is generated by the ArcGIS soft-
ware. The software determines the optimal (p) value for
Table 3 Genotype frequency calculation rubric
Mutant Frequency = Wildtype Frequency = Mixed Frequency =
Combined (Mu + Mi)/(Mu + Mi + Wt) Wt/(Mu + Mi + Wt) N/A
Excluded Mu/(Mu + Wt) Wt/(Mu + Wt) N/A
Separate Mu/(Mu + Wt + Mi) Wt/(Mu + Wt + Mi) Mi/(Mu + Wt + Mi)
Split (MAF only) (Mu + Mi)/[Mu + Wt + (2 × Mi)] (Wt + Mi)/[Mu + Wt + (2 × Mi)] N/A
N/A Mi not described.
Mutant frequency reported directly from study
Mi not described.
Wildtype frequency reported directly from study
N/A
Mu = number of isolates carrying pure mutant genotype
Mi = number of isolates carrying mixed mutant genotype
Wt = number of isolates carrying pure wildtype genotype
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Figure 1 Snapshot of prevalence - dhfr triple mutant genotype (N51I, C59R, S108N).
Sridaran et al. Malaria Journal 2010, 9:247
http://www.malariajournal.com/content/9/1/247
Page 7 of 22
Figure 2 Snapshot of prevalence - dhps double mutant genotype (A437G, K540E).
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the map by minimizing the root mean square prediction
error (RMSPE), which is a summary statistic that
describes the error of the prediction surface. A (p) value
of “0” means a given data point has equal influence on
all parts of the prediction surface regardless of the dis-
tance from the point. Whereas, a large (p) value means
the influence of a data point drops off very quickly as
the distance from the point increases. The optimal (p)
value for each map is shown in Figures 1 and 2.
The prediction surface of each map is shaded using a
gradient scheme consisting of quintiles. Areas of the
prediction surface considered to have a high prevalence
of mutant genotypes are denoted by darker shading,
whereas areas considered to have a lower estimated
mutant genotype prevalence are denoted by lighter
shading. The IDW spatial representation does not
account for the date of the study. Therefore, shaded
areas of the maps can only serve as crude snapshots of
mutant allele prevalence between 1993 and 2008 with
decreasing reliability as distance from observed data
points increases. The MARA [66] map describing
malaria transmission in Africa was used to restrict the
shading on the mutant genotype prevalence maps to
areas where malaria transmission is known to be
present.
Time plots were created (see Figures 3 and 4) to sup-
plement the maps by showing reported genotype fre-
quencies from individual studies over time using a
similar shading scheme. Each dot represents at least one
study conducted for that year. The darker shaded dots
on the time plot reflect higher mutant genotype preva-
lence, whereas the lower prevalence values are denoted
by lighter dots. Multiple studies conducted in the same
country and in the same year are still denoted by a sin-
gle dot whose color represents a weighted average of
the genotype frequency reported by each study. The
time plots and maps were created separately because a
geo-statistical map that accounts for several variables,
similar to the world malaria map put forth by Hay et al
[67], was not feasible given sample size limitations and
an inability to directly compare studies due to the
unknown impact of variables among molecular studies.
Statistical analysis of reported mutant genotype
frequencies and study variables
A multilevel mixed effects logistic regression model [68]
is used to determine how factors including: location of
study, year of study, type of study, age of sampled popu-
lation, and mixed genotype categorization are associated
with the reported frequency of the dhfr triple mutant
and dhps double mutant genotypes in Africa. This
belongs to the class of generalized linear mixed models
which has been well established in both theoretical and
applied academic literature [69,70]. Furthermore, such
models have also been applied to meta-analysis of clini-
cal or observational studies [71-73]. In the model for
the dhfr triple mutant genotypes (Figure 5), the study
and country of the study are included as nested inter-
cept random effects in order to model the variability of
the probability of mutation between studies within a
country and also between countries. This induces a cor-
relation between individuals within the same study and
between studies within the same country. In the model
for the dhps double mutant genotype (Figure 6), only
the study random intercept effect is included due to
inestimability of the country random effect. This still
induces a correlation between individuals within the
same study; however, in this model, studies within the
same country are considered to be independent. The
remaining factors: year of study, type of study, age of
sampled population, and mixed genotype categorization
are considered fixed effects in the regression model.
The year of study is centered at the year of the first
study observed, 1993. Hence a study conducted in 1993
is given a year of 0, and a study conducted in 2005 is
given a year of 12. This convention is used to facilitate
interpretation of the intercepts as representing the prob-
ability of mutation at the start of the study time period
(1993), and also helps to avoid convergence issues in fit-
ting the model [74]. Year enters the model as a continu-
ous variable; various categorizations of year were
considered but deemed unnecessary. The type of study
is a dichotomous variable that describes each study as
either a clinical study or a survey. Studies that only
sampled from a population of individuals symptomatic
for uncomplicated malaria are considered clinical;
whereas, studies that sampled from an asymptomatic
population are considered surveys.
The fixed effect representing the age of sampled popu-
lation are divided into five age categories: 1) adolescents
and adults, 2) children and adolescents, 3) children
under 6 years, 4) mixed ages, 5) N/A. For this study,
individuals age 12 and under are considered children,
between 12 and 18 years of age are considered adoles-
cents, and age 18 or greater are considered adults. A
study is assigned to age category 1, 2, or 3 if greater
than 75% of the sampled population for that study fit
the category description. If the age of the sampled popu-
lation is described but did not meet the 75% threshold
then it is assigned to the mixed ages category. The N/A
category is used to describe studies that did not describe
the age of the sampled population.
The fixed effect representing mixed genotype categori-
zation is divided into four categories based on the meth-
odology used for reporting mixed genotypes: 1) separate,
2) combined, 3) excluded, and 4) N/A. The separate
category is assigned to studies that report mixed geno-
types separate from pure mutant or pure wildtype
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genotypes. The combined category is used to describe
studies that counted mixed genotypes as pure mutant
genotypes. The excluded category is used to describe
studies that completely removed mixed genotype data.
The N/A category is used to describe studies that did
not describe mixed genotypes in the study. The criteria
used to categorize studies based on reporting of mixed
genotype data is more thoroughly described in Table 3.
Statistical model
Let Yij be the number individuals with the mutant geno-
type in the jth study of the ith country. Conditional on
the fixed and random effects, Yij ~ Binomial(nij, πij),
where nij is the number of individuals in the j
th study of
the ith country. On the logit scale, the probability of
mutation πij is modeled as a linear combination of the
fixed and random effects. Equation (1) represents the
logistic regression model for dhfr triple mutant geno-
types, and equation (2) represents the logistic regression
model for the dhps double mutant genotypes.
logit v u xij i ij ij( ) = + + +  (1)
logit u xij ij ij( ) = + +  (2)
i = 1, ..., number of countries; j = 1, ..., number of stu-
dies in the ith country
Figure 3 Time plot of reported frequency - dhfr triple mutant genotype (N51I, C59R, S108N).
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Here, a is the fixed intercept, vi is the intercept random
effect of the ith country, uij is the intercept random effect
of the jth study in the ith country, and b is a vector repre-
senting the fixed study level effects. The study and coun-
try random intercepts allow the intercept to differ
between studies. For model (1) the country random
effects vi are assumed to be normally distributed vi ~ N
(0, sv, dhfr
2), while the study random effects uij are
assumed to be normally distributed uij ~ N(0, su, dhfr
2).
For the analysis of dhfr triple mutant genotypes, sv, dhfr2
represents the heterogeneity between countries, and su,
dhfr
2 represents the heterogeneity between studies within
a country. In model (2) the study random effects uij are
assumed to be normally distributed uij ~ N(0, su, dhps2),
and su, dhps
2 represents the heterogeneity between studies
of the dhps double mutant genotypes. The variance com-
ponents are estimated on the logit scale, and therefore do
not have a direct interpretation. Statistical analysis was
performed in R version 2.8.1 using the lmer function in
the lme4 package, which uses Laplace approximation to
the likelihood to obtain parameter estimates [75]. The
significance of the fixed effects is evaluated through stan-
dard likelihood ratio tests, and the significance of the var-
iance components for the random effects is evaluated
through likelihood ratio tests where the asymptotic distri-
bution of the likelihood ratio test statistic follows a mix-
ture of chi-squared distributions [76]; p-values less than
0.05 are considered statistically significant.
Results
Literature search and databases
The literature search of the PubMed database yielded
approximately 750 articles after search terms were
applied. Of these 750 articles, most were excluded
Figure 4 Time plot of reported frequency - dhps double mutant genotype (A437G, K540E).
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because they did not report the frequency of dhfr and/or
dhps genotypes. Of the remaining articles, several were
excluded on the basis of their location outside of Africa.
Few studies were excluded on the basis of other criteria
(ie. language of article not in English, travelers included
in the sample population, and drug administration prior
to molecular analysis). Data was successfully extracted
from 100 articles that yielded genotype frequency infor-
mation for 220 studies conducted in 31 African coun-
tries and published prior to 2009. Of these 220 studies,
207 studies reported the frequency of one or more
mutations of interest within the dhfr or dhps gene.
These mutations include dhfr A16V, C50R, N51I, C59R,
S108N/T, I164L and dhps S436A/F, A437G, K540E,
A581G, A613 S. Studies reporting the frequency of
these individual mutations are summarized in the
mutant allele frequency (MAF) database (Additional File
1). 161 studies reported the frequency of either the dhfr
triple mutant genotype (N51I, C59R, S108N) or the
dhps double mutant genotype (A437G and K540E), or
both. These data are summarized in the multiple muta-
tion (MM) database (Additional File 2).
Figure 5 Country and study level random effects - dhfr triple mutant genotype (N51I, C59R, S108N).
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Both the MAF and MGF databases are organized in
alphabetical order by country. Each entry within the
database reports mutant genotype frequency and
descriptive information including: the location of the
study, age of sampled population, categorization of
mixed genotype data, and year the study was conducted.
Study location is reported as specifically as possible and
is typically identified by a recognizable city or village;
however, in some cases, the location could only be
described on the scale of a region or district. Most stu-
dies provided the age of the sampled population with a
description of the age range. However, some also
reported the mean or median age of the sampled popu-
lation and these data are reported where available.
Mixed genotype categorization was based upon the
convention used in the study to describe how mixed
genotypes were considered when calculating genotype
frequencies; however, in many cases mixed genotypes
can be interpreted in multiple ways. For this review, the
default convention was to split the mixed genotype data
in the MAF database (Additional File 1) if the data per-
mitted this interpretation. However, the default conven-
tion was to report mixed genotype data separately in the
MGF database (Additional File 2) if the data permitted
this interpretation.
The MAF and MGF databases also report the date the
study was conducted. Studies were typically conducted
within the span of a single year; however, a number of
Figure 6 Study level random effect - dhps double mutant genotype (A437G, K540E).
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studies spanned a number of years. If a date range was
provided, the last year of the study was used for statisti-
cal analysis. The sample size of the study is given in the
MGF database; however, the sample sizes are not given
in the MAF database because the number of isolates
examined for each codon often varied.
Maps and time plots of dhfr triple mutant and dhps
double mutant genotypes
The maps shown in Figures 1 and 2 highlight two major
qualitative features: 1) the distribution of studies across
the continent and 2) the location of resistance hotspots.
The map describing the prevalence of the dhfr triple
mutant genotype across Africa (Figure 1) shows the
location of 159 studies. An examination of Figure 1 indi-
cates a strong reporting bias in favor of certain parts of
the continent. In fact, 43.9% of studies reporting the
prevalence of dhfr triple mutant genotype were con-
ducted in Kenya, Tanzania, and Cameroon alone. The
red shading on the map indicates very high prevalence
(> 70% of sampled isolates) of the dhfr triple mutant
genotype in parts of Cameroon, Uganda, Kenya, Tanza-
nia, and Malawi.
The map describing the prevalence of the dhps double
mutant genotype across Africa (Figure 2) shows the
location of 94 studies. The map also indicates that a
large number of studies were conducted around Kenya
and Tanzania; however, there are also several studies
reporting these data in southern Mozambique. A large
portion, 41.5% of total studies examining prevalence of
the dhps double mutant genotype, was conducted in
these three countries. Dark green shading in Figure 2
indicates high prevalence of the dhps double mutant in
parts of Uganda, Kenya, Tanzania, and Malawi.
A comparison of the dhfr triple mutant genotype map
and dhps double mutant genotype map indicates that
both had a high prevalence in overlapping areas of East
Africa; however, this is not the case in West Africa
where the dhps double mutant genotype had a much
lower prevalence. A comparison of the data shows that
56.1% of the isolates sampled in East Africa carry the
dhfr triple mutant genotype and 44.3% carry the dhps
double mutant genotype. However, in West Africa,
51.5% of sampled isolates carry the dhfr triple mutant
genotype and only 3.0% carry the dhps double mutant
genotype (see Table 4 for complete comparative
analysis).
The time plots (Figures 3 and 4) show the reported
frequency of both the dhfr triple mutant genotype and
dhps double mutant genotype for studies reported since
1993, respectively. Both plots reveal an increase in the
number of studies being conducted since 1993 that
report the frequency of these mutant genotypes in
Africa. Most studies were conducted around 2001, with
a majority between 1998 and 2004. The shading of the
points on the time plots suggests greater prevalence of
both the dhfr triple mutant genotype and dhps double
mutant genotype being reported in later studies in parts
of Uganda, Kenya, and Tanzania. The reported fre-
quency of both the dhfr triple and dhps double mutant
genotypes in individual studies appears to be constant
or even decreasing over time in a few countries. These
perceived “trends” have little support since historical
data is limited in these countries and the variation in
reported frequency of mutant genotypes, even among
studies within a single country, is high. Therefore, the
time plots serve primarily as a summary of the limited
data available and are not to be interpreted as an
authoritative estimate of countrywide trends.
Statistical analysis of mutant genotype prevalence and
study variables
Multilevel mixed-effects regression was used to assess
the association of several variables on the reported fre-
quency of both the dhfr triple mutant genotype and the
dhps double mutant genotype independently. For the
dhfr triple mutant genotype, the results from 14,109
individuals in 155 studies from 25 countries were ana-
lyzed; the number of studies per country ranges from j
= 1 to 26, and the size of the study ranges from nij = 3
to 453. The regression model for the dhfr triple mutant
genotype yielded study level and country level intercept
random effects (see Figure 5). The x-axis in Figure 5
indicates the random effect value and is centered at
zero, which is the theoretical mean of the country ran-
dom intercepts. The country level random effect, vi
(denoted by a dark filled circle), displays the variability
of the probability of mutation between countries. Having
a random intercept near zero implies that the study’s
country level random intercept in the logistic regression
model is close to the overall fixed continent intercept,
a. Countries with smaller random country effects are
estimated to have a lower probability of mutation at the
start of the study time period compared to countries
with larger random effects. The study level random
effects are nested within the country effects, and there-
fore are centered at the country level random effects.
The study level random effects (denoted by a hollow cir-
cle) are displayed as vi + uij and show the variability of
the probability of mutation between studies within the
same country. The y-axis of Figure 5 is ordered by the
country level random effect, from largest on top to
smallest on the bottom. The regression confirms signifi-
cant variation for both the study level (P <0.01) and
country level (P <0.01) random effect, with variation
between countries (1.56) larger than variation between
studies within a country (0.89). This suggests that there
is significant variability in mutant genotype frequency
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reported among different countries and among studies
within a specific country.
For the fixed effects, the year of the study is signifi-
cantly associated (P < 0.01) with the frequency of the
dhfr triple mutant genotype and has a positive para-
meter estimate. Therefore, the model suggests that, con-
ditional on the random effects, the reported frequency
of this genotype in Africa is increasing over time. Of the
three remaining variables that were examined, only
mixed mutant categorization had a significant (P = 0.01)
association with the reported frequency of the dhfr triple
mutant genotype. The combined, excluded, and N/A
categories all had a positive parameter estimates relative
to the separate category; however, only the combined
and excluded categories significantly differed from the
separate category. This suggests that studies reporting
mixed mutant genotypes as pure mutants or excluded
them completely tend to have significantly higher
reported frequency of the dhfr triple mutant genotype
than studies that did not describe mixed mutant geno-
types. The age of the sampled population and the type
of study (clinical or survey) were not significantly asso-
ciated with reported mutant genotype frequency. A
summary of model results for the dhfr triple mutant
genotype can be found in Table 5.
The model for the dhps double mutant genotype (see
Figure 6) consisted of much fewer observations than the
model for the dhfr triple mutant genotype. For the dhps
double mutant genotype, the results from 7,761 indivi-
duals in 91 studies from 22 countries were assessed; the
number of studies per country ranges from j = 1 to 15,
and the size of the study ranges from nij = 6 to 397.
Two studies conducted prior to 1990 (one in Kenya and
one in Zambia) were excluded from the statistical
analysis because they were conducted earlier and could
be too influential. A data shortage for the dhps double
mutant genotype analysis led to convergence issues that
did not allow for estimation of a country level random
effect. However, the study level effect was still included
in the model as a random intercept effect in order to
allow for variation in the probability of mutation at the
start of the study time period. As in Figure 5, the x-axis
Table 4 Snapshot of data summarized by maps and time plots
dhfr triple mutant genotype (N51I, C59R,
S108N)
dhps double mutant genotype (A437G,
K540E)
Number of studies 159 94
Mean year of study conducted 2000.79 2001.08
Std Dev year of study conducted 3.35 3.40
Percentage of studies in top three countries^ 43.4% 41.5%
Percentage of studies conducted in East Africa† 67.3% 74.5%
Percentage of studies conducted in West Africa† 32.7% 25.5%
Number of total isolates examined 14316 7959
Average number of isolates sampled per study 91.2 84.7
Percentage of total isolates carrying genotype** 54.6% 33.7%
Percentage of isolates carrying genotype in East
Africa†**
56.1% 44.3%
Percentage of isolates carrying genotype in West
Africa†**
51.5% 3.0%
^ This value serves as an indicator for the clustering of studies: Top three countries reporting dhfr triple mutant genotype are: Kenya, Tanzania, and Cameroon;
Top three countries reporting dhps double mutant genotype are: Kenya, Tanzania, and Mozambique
** Weighted average of genotype prevalence, raw data taken from (Additional File 2)
† East and West Africa were defined by the longitudinal line at 22.5°E
Table 5 Model results for dhfr triple mutant genotype
Variable Estimate Std. Error P-value
Year 0.33 0.04 < 0.01
Type
Survey Referent - -
Clinical -0.13 0.03 0.66
Age Category 0.66
Adolescents and adults Referent - -
Children and adolescents 0.05 0.43 0.91
Children under 6 0.05 0.45 0.91
Mixed ages -0.37 0.50 0.46
N/A -0.43 0.53 0.41
Mixed Mutants 0.01
Separate Referent - -
Combined 0.80 0.38 0.03
Excluded 1.11 0.40 0.01
N/A 0.21 0.32 0.50
Random Effects Variance Std Dev P-value
Country 1.56 1.25 < 0.01
Study within Country 0.89 0.94 < 0.01
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in Figure 6 indicates the random effect value and is cen-
tered at the theoretical value of zero. Figure 6 differs
from Figure 5 in that a country level random effect
could not be estimated in Figure 6; therefore, the y-axis
of Figure 6 is ordered by the average study level random
effect for each country, from largest on top to smallest
on the bottom. Variation between studies for the analy-
sis of the dhps double mutant genotype is highly signifi-
cant (P < 0.01) and is estimated to be 8.83. This is
much larger than the between or within country varia-
tion observed in the analysis of the dhfr triple mutant
genotype because the variance for the dhps double
mutant genotype could not be partitioned. This suggests
that there is significant variability in the reported fre-
quency of the dhps double mutant genotype among dif-
ferent studies at the start of the study time period.
The year of the study is significantly associated (P
<0.01) with the reported frequency of the dhps double
mutant genotype and has a positive parameter estimate.
Therefore, the model suggests that, on average, mutant
prevalence is increasing over time in Africa. The three
remaining variables that were examined; mixed mutant
categorization, age of sampled population, and type of
study, were not significantly associated with the reported
frequency of the dhps double mutant genotype. A sum-
mary of model results for the dhps double mutant geno-
type can be found in Table 6.
Discussion
Broad inclusion criteria allowed most studies that report
the frequency of dhfr and/or dhps genotypes in Africa
to be included in this meta-analysis. The studies were
conducted as early as 1993 and as late as 2006; however,
the distribution is skewed (mean year: ~2001 for studies
reporting either multiple mutant genotype) towards
recent years reflecting an increase in the number of stu-
dies reporting the frequency of the dhfr triple mutant
and/or dhps double mutant genotypes. This observation
is in line with the increase in the number of anti-malar-
ial clinical efficacy trials reported in the literature in
recent years [77] and likely reflects the growing prioriti-
zation and feasibility of surveillance as a component of
malaria control strategies. 161 studies assembled in this
meta-analysis collectively examined blood isolates
derived from over 14,000 individuals for the dhfr triple
mutant genotype and nearly 8,000 individuals for the
dhps double mutant genotype. The clear emphasis on
reporting the dhfr triple mutant genotype is likely due
to its emergence some 10-20 years earlier than the dhps
double mutant genotype in Africa [78] and its ubiqui-
tous presence across the continent. The dhps double
mutant genotype (437G/540E), on the other hand,
emerged much later in the early to mid-1990’s [79] and
is only prevalent in East Africa with a small number of
cases reported in West Africa. The 436A/437G double
mutant appears to be emerging in West Africa with
apparent absence of 437G/540E double mutant genotype
in some countries. The prevalence of individual 436A
and 437G alleles have been summarized (see Additional
File 1). However, the 436A/437G double mutant geno-
type was not independently summarized due to limited
reporting of data on this genotype.
The maps describing the prevalence of the dhfr triple
mutant genotype (Figure 1) and dhps double mutant
genotype (Figure 2) illustrate a high concentration of
studies in certain parts of the continent. This observa-
tion clearly demands an assessment of potential sources
of reporting bias. A wealth of data in particular areas is
due in part to the availability of research capacity in
these areas to facilitate such studies. However, it is also
due to molecular surveillance studies conducted more
recently in some countries that provide a vast amount
of data compared to traditional molecular studies that
complement clinical efficacy trials. In fact, a majority of
the multiple mutant genotype data available from
Mozambique, Uganda, and Cameroon comes from just a
few surveillance studies [80-83] that examined a large
number of isolates from many sites within each country.
Surveillance studies in Kenya [84] and Tanzania [63,85]
also contributed a significant amount of molecular data
relative to traditional molecular studies. Potential
Table 6 Model results for dhps double mutant genotype
Variable Estimate Std. Error P-value
Year 0.57 0.14 < 0.01
Type
Survey Referent - -
Clinical -0.78 1.11 0.49
Age Category 0.22
Adolescents and adults Referent - -
Children and adolescents 2.86 2.29 0.21
Children under 6 4.11 2.40 0.09
Mixed ages 3.90 2.34 0.10
N/A 4.21 2.53 0.10
Mixed Mutants 0.90
Separate Referent - -
Combined 069 1.15 0.55
Excluded 0.74 1.13 0.51
N/A 0.42 1.06 0.69
Random Effects Variance Std Dev P-value
Study 8.83 2.97 < 0.01
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reporting and publication bias must also be considered
when examining the snapshots of resistance hotspots in
Figures 1 and 2. Areas where studies are concentrated
appear to coincide with areas where there has been a
higher reported frequency of the multiple mutant geno-
type. This may be due in part to bias in which molecu-
lar studies that show a high prevalence of mutant
genotypes are more likely to be published than those
that show little or no prevalence. Another potential
explanation is that traditional molecular studies often
complement clinical efficacy trials and are more likely to
be conducted in areas where therapeutic failure rates are
high and there is greater interest in the role resistance
mechanisms may be playing.
This meta-analysis shows that there are some impor-
tant differences in the reported frequency of the dhfr tri-
ple mutant genotype and dhps double mutant genotype.
Specifically, the dhfr triple mutant genotype appears to
be found in high prevalence in areas throughout the
continent whereas the dhps double mutant genotype
only appears to be prevalent in parts of East Africa. This
observation corroborates findings published by Pearce et
al, which also illustrated high prevalence of the dhps
mutant genotype consisting of A437G, K540E in East
Africa and low prevalence in West Africa. A number of
factors such as the early emergence of the dhfr triple
mutant genotype in Africa [78], pervasive drug pressure
from the distribution of pyrimethamine salts for malaria
prophylaxis in various parts of the world [86], and
human migration patterns [87], may explain the greater
distribution of this genotype throughout the continent.
Another important difference between the dhfr triple
mutant genotype and dhps double mutant genotype is
the impact of varying reporting conventions for mixed
genotype data. This study establishes that reporting con-
ventions for mixed genotypes has a significant impact
on the reported frequency of the dhfr triple mutant gen-
otype. However, this was not observed for the reported
frequency of the dhps double mutant genotype. This
may be explained by differences in diversity for the dhfr
and dhps genotypes found in Africa. Parasite popula-
tions that have greater diversity for a particular gene (ie.
more than one genotype in high prevalence circulating
in the population) are more likely to yield mixed geno-
types than parasite populations that have a low diversity
for a particular gene. Thus, differences in the way mixed
genotypes are reported have a more pronounced effect
on the prevalence rates reported for a gene that has
greater diversity in a given population than one that
does not. It has been shown that the dhps (A437G,
K540E) mutant genotype is either ubiquitously present
or absent in most of the populations where it has been
examined [79]; therefore, polyclonal infections contain-
ing the dhps double mutant genotypes along with
another dhps mutant genotype are less likely to occur.
However, the dhfr triple mutant genotype has histori-
cally been found alongside a higher prevalence of sensi-
tive, single, and double mutant dhfr genotypes
circulating in the population [87,88]; therefore, mixed
genotypes are more likely to occur, particularly in earlier
studies before the triple mutant dhfr genotype became
fixed in the population. This phenomenon may explain
why reporting conventions for mixed genotype data was
significantly associated with the reported frequency of
the dhfr triple mutant genotype but not the dhps double
mutant genotype.
The specific reasons responsible for the differential
impact of reporting conventions for mixed genotype
data on the reported frequency for either mutant geno-
type examined in this meta-analysis are difficult to iden-
tify and may also be an artifact of confounding variables
that were not accounted for in the statistical regression
used herein. Regardless, the fact remains that polyclonal
infections commonly occur in many of the high trans-
mission settings across Africa and the characterization
of mixed genotypes is an issue that must be addressed.
Novel methods for analyzing mixed infections [89], mul-
tivariate in vitro studies, and standardized interpretation
of existing mixed genotype data [32] have all been pro-
posed as methods to better characterize mixed geno-
types and present promising avenues for the future.
Although there are a number of differences in the distri-
bution and prevalence of the dhfr triple mutant geno-
type and dhps double mutant genotype, there are also
some similarities - The prevalence of both alleles is
increasing on average in Africa. On average, the age and
clinical status of the sampled population are not signifi-
cantly associated with the reported frequency of either
mutant genotype. This is in contrast to smaller regional
studies that have shown association between age, treat-
ment failure rate, and the prevalence of genetic markers
for resistance [90,91]. The observations from this meta-
analysis that suggest there is not a significant association
between these factors should not be seen as a contradic-
tion to more localized studies; rather, they testify to lim-
itations that are inherent in meta-analyses, particularly
in identifying regional trends. These limitations must be
specifically addressed in order to contextualize the
observations made in this study and appropriately
articulate the conclusions that can be drawn from them.
One of the major limitations in this meta-analysis was
the small number of variables that could be assessed in
the statistical models. There are a number of clinical
and epidemiological variables such as transmission,
regional drug administration policies, and target popula-
tions (ie. pregnant women, co-infections, etc.) that may
better explain the reported frequency of the dhfr triple
mutant and dhps double mutant genotypes but could
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not be examined in this analysis. This was due to lack of
power from limited datasets and inability to link these
data to reported frequency data where this information
was not specifically reported.
Another limiting factor that must be considered when
making statements regarding trends across the continent
is the confounding effect of space and time. The studies
reporting the frequency of the dhfr and dhps multiple
mutant genotypes included in this analysis were con-
ducted over a period of 13 years. In most cases, the data
from a particular country only spans a fraction of this
13 year period; therefore, there is a regional bias where
data from a particular year is really a reflection of cer-
tain regions, not the continent as a whole. The sample
size of studies included in the analysis may have also
contributed to regional and temporal bias since the
regressions were weighted. The mean study size was 90
isolates for studies reporting the dhfr triple mutant gen-
otype and 85 isolates for studies reporting the dhps dou-
ble mutant genotype. However, studies examined as few
as 3 isolates and as many as 453 isolates (approximately
5% of the total number of studies had sample sizes of
fewer than 15 isolates). Since studies that have small
sample sizes are more likely to be skewed by rare events
[92], and these smaller studies tend to occur in more
remote areas, this means that remote areas may not be
as accurately represented by reported frequency data. In
light of these factors, it is more appropriate to consider
the data conveyed by the maps and regressions as snap-
shots of cumulative mutant genotype data rather than a
description of mutant genotype frequency at any specific
point in space or time.
Finally, accessibility to studies and the interpretation
of data from included studies that use different report-
ing conventions represented noteworthy sources of bias
and error, respectively. The literature search in this
study was limited to the Pubmed database and Cochrane
Library. Molecular studies that were not available
through these sources are not reported. Studies that
were included still required a level of interpretation due
to differences in methodological and reporting conven-
tions; some of which were specifically examined in this
meta-analysis. However, many of these aspects simply
could not be addressed within the scope this study.
Since there is no established format for the collection
and dissemination of molecular data, there was difficulty
in determining if molecular data for the same samples
was published multiple times in different articles. Efforts
were made to filter out articles that reported data from
isolates that were already described in a different article;
however, there was uncertainty for some articles and it
is possible that molecular data for some isolates were
reported twice and others were excluded unnecessarily.
Conclusion
This database, despite its limitations, provides a centra-
lized source for information describing the frequency of
mutant dhfr and dhps genotypes in Africa that are
known to confer anti-folate resistance. These data col-
lectively show that the dhfr triple mutant genotype con-
sisting of (N51I, C59R, S108N) is fixed in several parts
of Africa and has been increasing, on average, over the
time period from 1993 to 2006. The dhps double
mutant genotype consisting of (A437G and K540E) also
increased in prevalence, on average, during the same
time period. However, this genotype appears to only be
fixed in parts of East Africa while its prevalence in West
Africa remains low. Continued drug pressure with SP
may contribute to further selection of quadruple dhfr
mutant genotypes and triple dhps mutant genotypes in
Africa; similar to what has been observed in Asia and
South America. The increasing prevalence and fixation
of these mutant genotypes has historically been asso-
ciated with a loss of anti-folate drug efficacy and may
pose a threat to settings in Africa where anti-folates are
still used to treat clinical malaria.
SP is currently used in sub-Saharan Africa for IPTp.
In this context, the drug is used to clear P. falciparum
infection in women with acquired immunity and usually
low density asymptomatic parasitaemia. Thus, the treat-
ment efficacy of SP for clinical malaria in young chil-
dren cannot be directly extrapolated to its usefulness for
IPTp [93]. However, a recent study by Harrington et al.
[94] in Muheza, Tanzania shows that IPTp was asso-
ciated with increased parasitemia and a higher degree of
placental inflammation. The study also demonstrates
selection of the resistance allele at dhps codon 581 in
women receiving IPTp. In a subsequent study involving
young children from Tanzania, emergence of triple
mutant dhps allele with mutations in codons 437, 540
and 581 has been confirmed and this coincided with the
high rate of therapeutic failure [95]. In the same report,
preliminary data reporting the spread of parasites with
dhps mutation at codon 581 to other parts of Africa has
been presented. These findings suggest that the spread
of the highly resistant triple mutant dhps allele along
with triple/quadruple mutant dhfr alleles in different
parts of Africa could further compromise the effective-
ness of SP for the treatment of falciparum malaria and
may have implications for IPTp. Therefore, systematic
molecular surveillance studies coupled with assessment
of drug effectiveness, including in pregnant women
receiving IPTp, will be critical in the future to correlate
molecular surveillance data with SP efficacy.
A continuation of efforts to conduct systematic mole-
cular surveillance will further provide valuable informa-
tion needed to construct future iterations of resistant
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genotype maps and databases; however, standardized
methodology and reporting conventions are critical to
improve the resolution and statistical power of centra-
lized information systems. Challenges confronted during
this meta-analysis suggest that patient specific data,
standardized characterization of mixed genotypes, more
specific date and locality descriptions, and better design
and distribution of molecular studies are all critical
objectives that must be pursued in order to fulfill the
vision of the centralized resistance network proposed by
WWARN.
Additional material
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identification number
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